Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The U.S. Food and Drug Administration sent an unfavorable Complete Response Letter last week to Agile Therapeutics Inc (NASDAQ:AGRX) regarding approval for the Twirla contraceptive patch. The letter also included concerns at a third-party manufacturer, Corium International Inc (NASDAQ:CORI).
The Analyst
H.C. Wainwright & Co.'s Oren Livnat maintains a Buy rating on Corium's stock with a price target lowered from $15 to $14.
The Thesis
Agile's receipt of a Complete Response Letter was "surprising" given the therapy's robust clinical package and a "very compelling" risk-benefit profile, Livnat said in a Wednesday note. (See Livnat's track record here.)
The deficiencies cited by the FDA were focused on the patch adhesion testing methods, manufacturing "483" observations at Corium and potential read-across of adhesion issues in the Twirla Phase 3 result, according to H.C. Wainwright.
Systemic manufacturing issues at Corium are unlikely, and the problems are "few and minor," with no negative read-through to the company's patch technology platform or pipeline, Livnat said.
The FDA's letter isn't a "deal breaker" for Twirla, the analyst said, and the FDA could approve the therapy in one year — but an FDA meeting scheduled for the first quarter of 2018 may accelerate the approval timeline.
The FDA letter's referernce to adhesion issues points to caution on the agency's part in making sure no issues specific to the patch result in higher pregnancy rates versus approved contraceptives, Livnat said.
"Hopefully, Agile's detailed Phase data showing no correlation between adhesion and efficacy will quickly put the FDA's mind back at ease, and Twirla can be approved in 2018."
Price Action
Shares of Corium were trading slightly higher at $10.01 at the time of publication Wednesday.
Corium to Join NASDAQ Biotechnology Index
Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!